115 related articles for article (PubMed ID: 6697430)
1. Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice.
Dufour M; St Germain J; Skalski V; Dorato A; Lazarus P; Panasci LC
Cancer Chemother Pharmacol; 1984; 12(2):94-7. PubMed ID: 6697430
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of decrease of protein synthesis by sodium cyanate in murine P388 leukemia cells.
Lazarus P; Panasci LC
Cancer Res; 1987 Oct; 47(19):5102-7. PubMed ID: 3621195
[TBL] [Abstract][Full Text] [Related]
3. Alteration of the systemic antitumor activity of melphalan by sodium cyanate in MOPC-460D myeloma-bearing BALB/c mice.
Shenouda G; Hutchinson M; Noë A; Panasci L
J Surg Oncol; 1993 Feb; 52(2):110-4. PubMed ID: 8468973
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
Cantrell JE; Green D; Schein PS
Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
[TBL] [Abstract][Full Text] [Related]
6. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
7. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.
Neil GL; Kuentzel SL; McGovren JP
Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal chemotherapy with melphalan plus glutaminase.
Holcenberg J; Anderson T; Ritch P; Skibba J; Howser D; Ring B; Adams S; Helmsworth M
Cancer Res; 1983 Mar; 43(3):1381-8. PubMed ID: 6825107
[No Abstract] [Full Text] [Related]
9. 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity.
Schein PS; Green D; Dean SW; McPherson E
Cancer Res; 1987 Feb; 47(3):696-9. PubMed ID: 3802075
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
11. Influence of concomitant infusion of thymidine and inosine on methotrexate activity in normal and P388-bearing mice.
Uitendaal MP; Schornagel JH; Leyva A; Pinedo HM
Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1527-32. PubMed ID: 6542016
[TBL] [Abstract][Full Text] [Related]
12. Effect of thymidine on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II).
Grossie VB; Valdivieso M; Drewinko B; Loo TL
Cancer Chemother Pharmacol; 1984; 13(1):27-30. PubMed ID: 6539657
[TBL] [Abstract][Full Text] [Related]
13. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
Shinoda H; Inaba M; Tsuruo T
Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium cyanate in mice bearing B16 melanoma.
Lea MA; Luke A; Velazquez O; Carpenter L; Martinson CF; Hill HZ; Hill GJ
Cancer Chemother Pharmacol; 1986; 17(3):231-5. PubMed ID: 3742708
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
17. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by squalene of antitumor effect of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-nitros ourea in a murine tumor system.
Yamaguchi T; Nakagawa M; Hidaka K; Yoshida T; Sasaki T; Akiyama S; Kuwano M
Jpn J Cancer Res; 1985 Oct; 76(10):1021-6. PubMed ID: 3935620
[TBL] [Abstract][Full Text] [Related]
19. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel JA; Wodinsky I
Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice.
Keizer HJ; Pauwels R; Landuyt W; Balzarini J; van der Schueren E; De Clercq E
Cancer Lett; 1988 Mar; 39(2):217-23. PubMed ID: 3359416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
